CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Cytovia Therapeutics
Main focus: Next-generation iPSC-derived cell therapies
Company stage: Pre-clinical
Diseases (gene editing): Solid tumours, Multiple myeloma
Genome editing tool: TALEN, CRISPR
Funding stage: Private
Location: Aventura, Florida and New York, USA
Website: https://www.cytoviatx.com/
Pipeline: https://www.cytoviatx.com/our-products
Gene editing partnerships: Cellectis
Cytovia Therapeutics is a privately-held biotech company focused on the development of iPSC-derived natural killer (NK)- and CAR-NK cell therapies. The company uses CRISPR as well as TALEN technology, which it has licensed from Cellectis, for genomic editing of its NK cell candidates.
